Palbociclib in hormone-receptor-positive advanced breast cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer. METHODS: This phase 3 study involved 521 patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that had relapsed or progressed during prior endocrine therapy. We randomly assigned patients in a 2:1 ratio to receive palbociclib and fulvestrant or placebo and fulvestrant. Premenopausal or perimenopausal women also received goserelin. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, objective response, rate of clinical benefit, patient-reported outcomes, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 195 events of disease progression or death had occurred. RESULTS: The median progression-free survival was 9.2 months (95% confidence interval [CI], 7.5 to not estimable) with palbociclib-fulvestrant and 3.8 months (95% CI, 3.5 to 5.5) with placebo-fulvestrant (hazard ratio for disease progression or death, 0.42; 95% CI, 0.32 to 0.56; P<0.001). The most common grade 3 or 4 adverse events in the palbociclib-fulvestrant group were neutropenia (62.0%, vs. 0.6% in the placebo-fulvestrant group), leukopenia (25.2% vs. 0.6%), anemia (2.6% vs. 1.7%), thrombocytopenia (2.3% vs. 0%), and fatigue (2.0% vs. 1.2%). Febrile neutropenia was reported in 0.6% of palbociclib-treated patients and 0.6% of placebo-treated patients. The rate of discontinuation due to adverse events was 2.6% with palbociclib and 1.7% with placebo. CONCLUSIONS: Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an interim analysis reported PFS of 9.2 months with palbociclib-fulvestrant and 3.8 months with placebo-fulvestrant (hazard ratio 0.42)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
In the citing paper
“This study enrolled pre- and peri-menopausal patients, with benefit of the combination observed across groups.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [84]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationThe history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Cited by
Items 401–500 of 1,000
Cell cycle regulation and hematologic malignancies
Dai, Y., Jin, F., Wu, W., & Kumar, S. K. (2019) · Blood Science · doi:10.1097/bs9.0000000000000009 · Cited by 48
Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer
Goel, B., Tripathi, N., Bhardwaj, N., & Jain, S. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516152756 · Cited by 48
Klein, S., Quaas, A., Noh, K., Cartolano, M., Abedpour, N., Mauch, C., Quantius, J., Reinhardt, H. C., Buettner, R., Peifer, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1899 · Cited by 47
Rozenblit, M., Mun, S., Soulos, P. R., Adelson, K. B., Pusztai, L., & Mougalian, S. S. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01394-y · Cited by 46
The Breast Cancer Therapy Expert Group (BCTEG), Abraham, J., Coleman, R. E., ELIAS, A. D., Holmes, F. A., Kalinsky, K. M., Kittaneh, M., Lower, E. E., Mahtani, R. L., Mamounas, E., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4783-1 · Cited by 49
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer
Zhang, K., Hong, R., Lee, K., Xu, F., Xia, W., Qin, G., Zheng, Q., Lu, Q., Zhai, Q., Shi, Y., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.005 · Cited by 48
Self-citationManagement of Adverse Events Due to Cyclin-Dependent Kinase 4/6 Inhibitors
Ettl, J. (2019) · Breast Care · doi:10.1159/000499534 · Cited by 52
Abbas, S. E.-S., George, R. F., Samir, E. M., Aref, M. M. A., & Abdel‐Aziz, H. A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0050 · Cited by 45
Gul, A., Leyland-Jones, B., Dey, N., & De, P. K. (2018) · Europe PMC (PubMed Central) · Cited by 48
Maskey, R. S., Wang, F., Lehman, E., Wang, Y., Emmanuel, N., Zhong, W., Jin, G., Abraham, R. T., Arndt, K. T., Myers, J. S., et al. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1859195 · Cited by 51
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 47
Kraus, A. L., Yu‐Kite, M., Mardekian, J., Cotter, M. J., Kim, S., Decembrino, J., Snow, T., Carson, K. R., Rockland, J. M., Gossai, A., et al. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2454 · Cited by 47
Abdelmalak, M., Singh, R., Anwer, M. I., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A. W., Du, Y., Jiao, X., & Pestell, R. G. (2022) · Cancers · doi:10.3390/cancers14215388 · Cited by 50
Mayer, E. L., Fesl, C., Hlauschek, D., Garcia-Estevez, L., Burstein, H. J., Zdenkowski, N., Wette, V., Miller, K. D., Balic, M., Mayer, I. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01918 · Cited by 44
Self-citationMechanisms of endocrine resistance in hormone receptor-positive breast cancer
Gao, Y., Yu, Y., Zhang, M., Yu, W., & Kang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1448687 · Cited by 50
Colón‐Otero, G., Weroha, S. J., Foster, N. R., Haluska, P., Hou, X., Wahner-Hendrickson, A. E., Jatoi, A., Block, M. S., Dinh, T. A., Robertson, M. W., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.020 · Cited by 44
Advances in systemic therapy for metastatic breast cancer: future perspectives
Corona, S. P., Sobhani, N., Ianza, A., Roviello, G., Mustacchi, G., Bortul, M., Zanconati, F., & Generali, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0975-5 · Cited by 48
Brufsky, A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.004 · Cited by 50
Ettl, J., Im, S., Ro, J., Masuda, N., Colleoni, M. A., Schnell, P., Bananis, E., Lu, D. R., Cristofanilli, M., Rugo, H. S., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01263-0 · Cited by 46
“The pooled population included a total of 875 patients who received palbociclib plus ET (PALOMA-1, n = 84; PALOMA-2, n = 444; PALOMA-3, n = 347) [3, 4, 6].”
Self-citationNetwork-principled deep generative models for designing drug combinations as graph sets
Karimi, M., Hasanzadeh, A., & Shen, Y. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa317 · Cited by 45
“Breast cancer: Reverse resistance Endocrine therapies, including Fulvestrant, are the main treatment for hormone receptor-positive breast cancers (80% of breast cancers) (Turner et al., 2015).”
BackgroundCDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
Nardone, V., Barbarino, M., Angrisani, A., Correale, P., Pastina, P., Cappabianca, S., Reginelli, A., Mutti, L., Miracco, C., Giannicola, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168391 · Cited by 49
Bansal, I., Pandey, A. K., & Ruwali, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1244597 · Cited by 44
“Patients with advanced breast cancer that expresses hormone receptors but lacks HER2 had improved progression-free survival after receiving this combination (Turner et al., 2015).”
BackgroundERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
Reese, J. M., Bruinsma, E. S., Monroe, D. G., Negron, V. C., Suman, V. J., Ingle, J. N., Goetz, M. P., & Hawse, J. R. (2017) · Oncotarget · doi:10.18632/oncotarget.21787 · Cited by 47
Expression of miRNA‑206 and miRNA‑145 in breast cancer and correlation with prognosis
Quan, Y., Huang, X., & Quan, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.9440 · Cited by 48
Targeting MYCN in Molecularly Defined Malignant Brain Tumors
Borgenvik, A., Čančer, M., Hutter, S., & Swartling, F. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626751 · Cited by 46
Lin, D. I., Huang, R. S. P., Mata, D. A., Decker, B. J., Danziger, N. A., Lechpammer, M., Hiemenz, M., Ramkissoon, S. H., Ross, J. S., & Elvin, J. A. (2021) · Modern Pathology · doi:10.1038/s41379-021-00873-z · Cited by 44
Campos, J. F., Besson, T., & Raboin, S. (2022) · Pharmaceuticals · doi:10.3390/ph15030352 · Cited by 45
Abu-Khalaf, M. M., Hodge, K. A., Hatzis, C., Baldelli, E., Gazzah, E. E., Valdes, F., Sikov, W. M., Mita, M. M., Denduluri, N., Murphy, R., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00360-5 · Cited by 50
Li, X., Seebacher, N. A., Garbutt, C., Ma, H., Gao, P., Xiao, T., Hornicek, F. J., & Duan, Z. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0474-4 · Cited by 41
Renewed interest in the progesterone receptor in breast cancer
Lim, E., Palmieri, C., & Tilley, W. D. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.303 · Cited by 46
Can CDK4/6 inhibitors cause fatal lung injury?
Jazieh, K., Budd, G. T., Dalpiaz, N., & Abraham, J. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1674651 · Cited by 44
Development of cell-cycle checkpoint therapy for solid tumors
Tamura, K. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv131 · Cited by 47
Lousberg, L., Collignon, J., & Jérusalem, G. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016665077 · Cited by 43
Costa, R. L. B., Carneiro, B. A., Wainwright, D. A., Santa-Maria, C. A., Kumthekar, P., Chae, Y. K., Gradishar, W. J., Cristofanilli, M., & Giles, F. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw532 · Cited by 44
Self-citationAbemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
Palumbo, A., Lau, G., & Saraceni, M. M. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018795146 · Cited by 45
Nucleophilic amination of methoxypyridines by a sodium hydride–iodide composite
Pang, J., Kaga, A., & Chiba, S. (2018) · Chemical Communications · doi:10.1039/c8cc05979a · Cited by 44
Lin, Z., Zhang, X., Zhao, F., & Ru, S. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.01.017 · Cited by 50
Messer, J. A., Ekinci, E., Patel, T. A., & Teh, B. S. (2019) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2019.03.001 · Cited by 44
Grande, E., Teulé, À., Alonso‐Gordoa, T., Jiménez‐Fonseca, P., Benavent, M., Capdevila, J., Custodio, A., Vera, R., Munárriz, J., Casta, A. L., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0033 · Cited by 44
“These drugs received US Food and Drug Administration and European Medicines Agency approval for the treatment of hormone receptor-positive and HER2-negative breast cancer in combination with either aromatase inhibitors or fulvestrant based on significant improvements in PFS [2].”
BackgroundLorito, N., Bacci, M., Smiriglia, A., Mannelli, M., Parri, M., Comito, G., Ippolito, L., Giannoni, E., Bonechi, M., Benelli, M., et al. (2020) · Cells · doi:10.3390/cells9030668 · Cited by 45
Xi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 47
Fasching, P. A., Beck, J. T., Chan, A., Laurentiis, M. D., Esteva, F. J., Jérusalem, G., Neven, P., Pivot, X. B., Bianchi, G., Martín, M., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.09.008 · Cited by 43
Zhang, Y., Ma, Z., Sun, X., Feng, X., & An, Z. (2022) · The Breast · doi:10.1016/j.breast.2022.02.011 · Cited by 46
“Methods: Electronic databases and ClinicalTrials.gov were searched from inception to October 1, 2021 for RCTs reporting the occurrence of LD/pneumonitis in cancer patients treated with CDK4/6 inhibitors.”
BackgroundInfluentialAl-Karmalawy, A. A., Eissa, M. E., Ashour, N. A., Yousef, T. A., Khatib, A. O. A., & Hawas, S. S. (2025) · RSC Advances · doi:10.1039/d5ra05472a · Cited by 48
Perez, E. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.001 · Cited by 43
Cyclin-dependent kinase pathways as targets for women's cancer treatment
Konecny, G. E. (2015) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000243 · Cited by 46
The molecular underpinnings of prostate cancer: impacts on management and pathology practice
Rodrigues, D. N., Boysen, G., Sumanasuriya, S., Seed, G., Marzo, A. M. D., & Bono, J. S. D. (2016) · The Journal of Pathology · doi:10.1002/path.4826 · Cited by 43
“Two independent groups have reported improvements in progression free-survival when the combination of palbociclib with hormonal therapy was compared to hormonal therapy alone in hormone receptor positive breast cancer [74, 75].”
Reinert, T., & Barrios, C. H. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728928 · Cited by 48
Rocca, A., Maltoni, R., Bravaccini, S., Donati, C., & Andreis, D. (2018) · Cancer Management and Research · doi:10.2147/cmar.s137772 · Cited by 45
Nguyen, L. V., Searle, K., & Jerzak, K. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27238 · Cited by 41
Peterson, L. M., Kurland, B. F., Yan, F., Novakova-Jiresova, A., Gadi, V. K., Specht, J. M., Gralow, J. R., Schubert, E. K., Link, J. M., Krohn, K. A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244459 · Cited by 43
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer
Wang, R., Xu, K., Gao, F., Huang, J., & Guan, X. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188590 · Cited by 44
Lim, C., Dismuke, T., Malawsky, D. S., Ramsey, J. D., Hwang, D., Godfrey, V., Kabanov, A. V., Gershon, T. R., & Sokolsky‐Papkov, M. (2022) · Science Advances · doi:10.1126/sciadv.abl5838 · Cited by 43
Liu, C., Hu, S., Xu, X., Zhang, Y., Wang, B., Song, S., & Yang, Z. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01555-7 · Cited by 42
Therapeutic Approaches for Zika Virus Infection of the Nervous System
Abrams, R. P. M., Solis, J., & Nath, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0575-2 · Cited by 44
Seize the engine: Emerging cell cycle targets in breast cancer
Fuentes‐Antrás, J., Bedard, P. L., & Cescon, D. W. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1544 · Cited by 42
Targeting CDK2 for cancer therapy
Knudsen, E. S., Witkiewicz, A. K., Sanidas, I., & Rubin, S. M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116140 · Cited by 43
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G. A., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0427 · Cited by 44
Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence
Dyhl-Polk, A., Kolmos, I. L., Kümler, I., & Nielsen, D. L. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000093 · Cited by 43
Igarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyaki, M., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Higuchi, T., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.119 · Cited by 43
Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes
Usary, J., Darr, D. B., Pfefferle, A. D., & Perou, C. M. (2016) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1438s72 · Cited by 43
MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma
Bustos, M. A., Ono, S., Marzese, D. M., Oyama, T., Iida, Y., Cheung, G., Nelson, N. E., Hsu, S. C., Yu, Q., & Hoon, D. S. �. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.039 · Cited by 41
“…growth arrest decreases the effect of palbociclib Considering the regulatory effects of miR-200a on CDK6 expression, the potential interactions with palbociclib, a CDK4/6 inhibitor recently approved by the US Food and Drug Administration, were evaluated (Beaver et al., 2015; Turner et al., 2015).”
BackgroundCersosimo, R. J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz121 · Cited by 42
Ha, M. J., Raghavendra, A. S., Kettner, N. M., Qiao, W., Damodaran, S., Layman, R. M., Hunt, K. K., Shen, Y., Tripathy, D., & Keyomarsi, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.33959 · Cited by 39
Shohdy, K. S., Lasheen, S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617722516 · Cited by 39
Phosphoproteomics in translational research: a sarcoma perspective
Noujaim, J. C., Payne, L. S., Judson, I. R., Jones, R. L., & Huang, P. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw030 · Cited by 42
Clinical development of CDK4/6 inhibitor for breast cancer
Iwata, H. (2018) · Breast Cancer · doi:10.1007/s12282-017-0827-3 · Cited by 39
Self-citationLee, C., Oh, P., Xu, E. S., Ma, Y., Kim, Y., Daniel, A. R., & Kirsch, D. G. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.07.192 · Cited by 41
“Blocking CDK4/6 does not alter radiosensitivity of human and mouse cancer cells in vitro.”
BackgroundInfluentialThibault, S., Hu, W., Hirakawa, B. P., Kalabat, D. Y., Franks, T., Sung, T., Khoh‐Reiter, S., Lu, S., Finkelstein, M. B., Jessen, B. A., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0734 · Cited by 38
Adamo, B., Bellet, M., Paré, L., Pascual, T., Vidal, M. J., Fidalgo, J. A. P., Blanch, S., Martínez-Jáñez, N., Murillo, L. S., Gómez-Pardo, P., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1195-z · Cited by 39
Shi, J., Lv, S., Wu, M., Wang, X., Deng, Y., Li, Y., Li, K., Zhao, H., Zhu, X., & Ye, M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.21 · Cited by 40
Sikora, M., Marycz, K., & Śmieszek, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.017 · Cited by 41
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
Zheng, J., Yu, Y., Durairaj, C., Dieras, V. C., Finn, R. S., & Wang, D. D. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00771-5 · Cited by 38
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Zhu, Z., Turner, N. C., Loi, S., André, F., Martín, M., Dieras, V. C., Gelmon, K. A., Harbeck, N., Zhang, C., Cao, J. Q., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00297-1 · Cited by 41
Self-citationUpdate on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies
Lerário, A. M., Mohan, D. R., & Hammer, G. D. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac012 · Cited by 41
Li, H., Wu, Y., Zou, H., Koner, S., Plichta, J. K., Tolaney, S. M., Zhang, J., He, Y.-W., Wei, Q., Tang, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105186 · Cited by 37
Tryfonidis, K., Başaran, G., Bogaerts, J., Debled, M., Dirix, L. Y., Théry, J., Tjan‐Heijnen, V. C. G., den Weyngaert, D. V., Čufer, T., Piccart, M. J., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.10.012 · Cited by 37
Novel strategies to improve the endocrine therapy of breast cancer
Castrellon, A. B. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.323 · Cited by 40
Kwon, N. H., Lee, J. Y., Ryu, Y.-L., Kim, C., Kong, J., Oh, S., Kang, B. S., Ahn, H. W., Ahn, S. G., Jeong, J., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00001 · Cited by 37
Watson, G. A., Deac, O. M., Aslam, R., O’Dwyer, R., Tierney, A., Sukor, S., & Kennedy, J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.002 · Cited by 38
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
Basudan, A., Priedigkeit, N., Hartmaier, R. J., Sokol, E. S., Bahreini, A., Watters, R. J., Boisen, M. M., Bhargava, R., Weiss, K. R., Karsten, M. M., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0946 · Cited by 40
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets
Milioli, H. H., Alexandrou, S., Lim, E., & Caldon, C. E. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0501 · Cited by 41
Yano, S., Tazawa, H., Kagawa, S., Fujiwara, T., & Hoffman, R. M. (2020) · Cancers · doi:10.3390/cancers12092655 · Cited by 40
Henry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 57
CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer
Lim, J. S. J., Turner, N. C., & Yap, T. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0563 · Cited by 39
Self-citationLasheen, S., Shohdy, K. S., Kassem, L. M. H., & Abdel-Rahman, O. M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1355242 · Cited by 38
Princic, N., Aizer, A. A., Tang, D. H., Smith, D. M., Johnson, W. E., & Bardia, A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1519500 · Cited by 36
Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, D., Volovăț, S. R., & Cardoso, F. (2018) · The Breast · doi:10.1016/j.breast.2018.10.001 · Cited by 40
The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Chan, T., Chin, Y. M., & Low, S. (2019) · Oncology and Therapy · doi:10.1007/s40487-018-0090-6 · Cited by 38
Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population
Clifton, K., Yi, M., Kimmel, J., Litton, J. K., Tripathy, D., & Karuturi, M. S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05181-4 · Cited by 36
Lamb, L. S., Sim, H., & McCormack, A. I. (2020) · Cancers · doi:10.3390/cancers12020308 · Cited by 37
“In particular, CDK4/6 inhibitors prolong progression-free survival and are now approved for use in estrogen receptor-positive breast cancer [97,98].”
BackgroundEarly treatment-related neutropenia predicts response to palbociclib
McAndrew, N. P., Dickson, M. A., Clark, A. S., Troxel, A. B., O’Hara, M. H., Colameco, C., Gallager, M., Gramlich, K., Zafman, K. B., Vaughn, D. J., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0967-7 · Cited by 37
How selective are clinical CDK4/6 inhibitors?
Hendrychová, D., Jorda, R., & Kryštof, V. (2020) · Medicinal Research Reviews · doi:10.1002/med.21769 · Cited by 38
The role of CDK4/6 inhibitors in early breast cancer
Gil‐Gil, M., Alba, E., Gavilá, J., de la Haba-Rodríguez, J., Ciruelos, E. M., Tolosa, P., Candini, D., & Llombart‐Cussac, A. (2021) · The Breast · doi:10.1016/j.breast.2021.05.008 · Cited by 37
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
Hertz, D. L., Henry, N. L., & Rae, J. M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0205 · Cited by 36
Yu, Z., He, S., Wang, D., Patel, H., Miller, C. P., Brown, J. L., Hattersley, G., & Saeh, J. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0670 · Cited by 48
The role of steroid hormones in breast cancer stem cells
Simões, B. M., Alférez, D., Howell, S. J., & Clarke, R. B. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0350 · Cited by 39
“However, the only approved targeted therapies to improve outcomes of endocrine-resistant ERC HER2K breast cancers are the mTOR inhibitor everolimus and the CDK4/6 inhibitor palbociclib combined with an AI or fulvestrant (Baselga et al. 2012, Finn et al. 2015, Turner et al. 2015).”
BackgroundPrior Authorization for Medications in a Breast Oncology Practice: Navigation of a Complex Process
Agarwal, A., Freedman, R. A., Goicuria, F., Rhinehart, C., Murphy, K. P., Kelly, E., Mullaney, E. E., Amand, M. S., Nguyen, P., & Lin, N. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.017756 · Cited by 35
Goodman, A. M., Choi, M. P., Wieduwilt, M. J., Mulroney, C. M., Costello, C. L., Frampton, G. M., Miller, V. A., & Kurzrock, R. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00004 · Cited by 35
Metadata
- Authors
- Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., Giorgetti, C., Randolph, S., Koehler, M., & Cristofanilli, M.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- National Cancer Center (KR)
- Institut Gustave Roussy (FR)
- The University of Melbourne (AU)
- Aichi Cancer Center Hospital (JP)
- Ludwig-Maximilians-Universität München (DE)
- German Breast Group (DE)
- Pfizer (United States) (US)
- Thomas Jefferson University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 209-219
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1464936406
- Cited by
- 1,590
- References
- 26
- Citations by year
- 2026: 67 · 2025: 142 · 2024: 117 · 2023: 109 · 2022: 127 · 2021: 142 · 2020: 172 · 2019: 123 · 2018: 169 · 2017: 193 · 2016: 179 · 2015: 49
- FWCI
- 154.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- The Medicine Forum (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Publications (Maastricht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, hormone receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, fulvestrant, progression-free survival, endocrine therapy resistance, neutropenia, febrile neutropenia, goserelin, metastatic breast cancer, G1/S transition, adverse events, overall survival
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Estradiol, Female, Humans, Middle Aged, Piperazines, Pyridines, Receptors, Estrogen, Receptors, Progesterone, Biomarkers, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.